19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyc…

Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") ...
Medscape

SBP and DBP measures together best predictor of CVD death, but pulse pressure still important

Bethesda, MD - A new analysis from the large Multiple Risk Factor Intervention Trial (MRFIT) cohort, confirms the importance of considering not just systolic or diastolic pressure, but both of these ...

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction ...

BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP ...

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 Cm Waist Circumference Decrease, Significant SBP/DBP Improvements Of 22.9/12.9 Mmhg, And 70.7 Μmol/L Uric Acid Reduction ...

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 Cm Waist Circumference Decrease, Significant SBP/DBP Improvements Of 22.9/12.9 Mmhg, And 70.7 Μmol/L Uric Acid Reduction Phase III Trial Meets ...